Targeting of IL-17A and/or its receptor is effective in treating psoriasis [47], and administration of secukinumab resolves plaque histopathology and reduces proinflammatory gene expression in patients with psoriasis [48]. The gene discussed is IL17A; the disease is psoriasis.